Final results from a prospective, multicenter, non-interventional study (BESREMi-PASS) on the safety of ropeginterferon alfa-2b in 229 patients with polycythemia vera
Veronika Buxhofer‐Ausch(Johannes Kepler University of Linz), Steffen Koschmieder(Integrated Oncology (United States)), Kurt Krejcy(AOP Orphan (Austria)), Charu Kohli(Hewlett-Packard (Austria)), Andreas Reiter(Heidelberg University), Stefanie Schlager(Hewlett-Packard (Austria)), Heinz Gisslinger(Medical University of Vienna), Christoph Klade(Intercell (Austria)), Albert Woelfler(University of Graz), Victoria Empson(AOP Orphan (Austria)), Ciprian Tomuleasa(Iuliu Hațieganu University of Medicine and Pharmacy), Luminita Ocroteala, Krauth Maria-Theresa(Medical University of Vienna), Lino L. Teichmann(University Hospital Bonn)
Cited by 0
Related Papers
Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study
|Journal of Clinical Oncology|2011|540
Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients
|Blood|2011|448